Journal of Inflammation Research (Aug 2021)

Symmetric Dimethylarginine is Altered in Patients After Myocardial Infarction and Predicts Adverse Outcomes

  • Gąsecka A,
  • Szwed P,
  • Jasińska K,
  • Fidali O,
  • Kłębukowska A,
  • Eyileten C,
  • Postula M,
  • Szarpak Ł,
  • Mazurek T,
  • Opolski G,
  • Filipiak KJ,
  • Ufnal M

Journal volume & issue
Vol. Volume 14
pp. 3797 – 3808

Abstract

Read online

Aleksandra Gąsecka,1 Piotr Szwed,1 Karolina Jasińska,1 Oliwia Fidali,1 Aleksandra Kłębukowska,1 Ceren Eyileten,2 Marek Postula,2 Łukasz Szarpak,3,4 Tomasz Mazurek,1 Grzegorz Opolski,1 Krzysztof J Filipiak,1 Marcin Ufnal5 1 1st Chair and Department of Cardiology, Medical University of Warsaw, Warsaw, 02-097, Poland; 2Department of Experimental and Clinical Pharmacology, Centre for Preclinical Research and Technology, Medical University of Warsaw, Warsaw, 02-097, Poland; 3Bialystok Oncology Center, Bialystok, 15-027, Poland; 4Maria Sklodowska-Curie Medical Academy in Warsaw, Warsaw, 03-411, Poland; 5Department of Experimental Physiology and Pathophysiology, Centre for Preclinical Research and Technology, Medical University of Warsaw, Warsaw, 02-106, PolandCorrespondence: Aleksandra Gąsecka 1st Chair and Department of Cardiology, Medical University of Warsaw, Banacha 1a, Warsaw, 02-097, PolandTel +48 22 599 19 51Email [email protected]: Acute myocardial infarction (AMI) is the leading cause of morbidity and mortality worldwide. Damage to the endothelium is the earliest event in atherothrombosis, including AMI. Nitric oxide (NO), an endothelium-derived compound, protects the vasculature from damage. This study evaluated whether an association exists between plasma concentration of endogenous NO-related pathway metabolites linked to AMI and major adverse cardiovascular events (MACE) after AMI.Methods: We compared plasma concentrations of NO-related pathway metabolites in patients after AMI (n=60) and healthy controls (n=27) and investigated the prognostic value of these metabolites for post-AMI MACE development over a median of 3.5-years. In search of biomarkers, we compared plasma concentrations of dimethylarginines (ADMA, SDMA), citrulline, arginine and ornithine using ultra performance liquid chromatograph coupled with a mass spectrometer.Results: Patients after AMI had higher concentrations of dimethylarginines, compared to controls (p=0.0068, p< 0.0001, respectively). Conversely, the concentration of citrulline was lower in the AMI group (p=0.0006). The concentration of SDMA was higher in patients who developed MACE than in those who did not (p=0.015). SDMA was the only independent predictor of MACE in multivariate analysis (p=0.023). There was an intermediate, negative correlation between plasma SDMA level and platelet reactivity (r=− 0.33, p=0.02).Conclusion: Plasma concentration of dimethylarginines differs between patients with AMI and healthy volunteers. The study’s novel finding is that SDMA is an independent predictor of MACE during a 3.5 year follow-up period after AMI.Keywords: nitric oxide, L-arginine, acute myocardial infarction, major adverse cardiovascular events, prognosis

Keywords